01 — At a Glance
The Bromine Company That Became a Battery Startup
- 52-Week High / Low₹1,868 / ₹967
- 9M FY26 Revenue₹577 Cr
- 9M FY26 PAT₹32.30 Cr
- Q3 FY26 Revenue₹220 Cr
- Q3 FY26 PAT₹4 Cr
- Book Value₹303
- Price to Book4.47x
- Debt / Equity1.41x
- Interest Coverage1.65x
- Fire Insurance Claim₹348.16 Cr
The Setup: Neogen Chemicals is the largest importer of lithium carbonate and hydroxide in India for the last three decades. But on March 5, 2025, their Dahej manufacturing plant caught fire and wiped out ₹348 crore in assets. They recognized the insurance claim. Then announced three new megasize plants. Then raised equity. Then formed a JV with Japan’s Morita Chemicals for battery salt manufacturing. Then declared FY27 battery revenue guidance of ₹400-500 crore. The market dusted its hands and sent the stock up 25% in three months. Either this is the plot of a Bollywood film, or the company is onto something massive.
02 — Introduction
From Bromine Boring to Battery Boom (The Plot Twist)
Neogen Chemicals was founded in 1991 by Haridas Kanani and for 32 years, the company did what it did best: manufactured bromine and lithium compounds for pharma, agrochemicals, and flavors. Solid business. Good margins. No drama. The stock traded at single-digit P/E multiples for half a decade. Dividend yield was aspirational. Retail investors confused it with their bathroom tiles.
Then someone woke up and realized: batteries are coming. And not just any batteries — lithium-ion batteries that need electrolytes, salts, additives. Every EV in the world needs them. India’s capacity is ramping. The US has 45X tax credits for non-China compliance. And the only proven manufacturing technology in India is being built by Mitsubishi and UBE (MUIS) — and Neogen just scored the exclusive license.
So what does Neogen do? Issues 10,00,000 shares at ₹1,610 to Cadamba Solutions (a promoter entity) in March 2026 — ₹161 crore. Raises ₹200 crore NCDs. Launches a $20 million JV with Japan’s Morita. Declares insurance claim of ₹348 crore. And tells the market: “We’re building three new plants that will make ₹1,000+ crore revenue by FY28.” The stock thought that was crazy. Then it went up 25% in three months anyway.
This is either the greatest contrarian opportunity or a masterclass in using investor FOMO to cover a manufacturing disaster. Let’s dig in — with data, humor, and the skepticism an auditor would bring to a claim this wild.
Feb 2026 Concall Note: “These are short-term impacts as we pivot to a future-ready portfolio.” — Management. Translation: Yes, our plant burned down. Yes, profit fell 63%. Yes, we’re now a pre-commercial battery company with ₹1,500 crore capex. But trust us, this is temporary. Pass the popcorn.
03 — Business Model: WTF Do They Even Do Now?
Bromine Niche Player Becoming Battery Vertical Shredder
Neogen operates across two legacy segments and one explosive new one. Organic chemicals (84% of revenue pre-battery): bromine compounds, advanced pharma intermediates, custom synthesis, contract manufacturing. Clients include Aurobindo, Sun Pharma, Hetero, Viatris. Margin-heavy, relationship-driven, recurring revenue. Boring. Profitable. Hated by growth investors.
Inorganic chemicals (16% of revenue): lithium-based products, specialty chemicals for polymers and construction. Margin-compressed due to commodity lithium price swings. But this is the stepping stone into the real play.
Neogen Ionics (the new beast): Battery electrolytes, lithium electrolyte salts (LiPF6), and additives. Q3 FY26 revenue was ₹12 crore. Guidance for FY27 is ₹400-500 crore. That’s 33x-40x growth in 12 months. If executed, this becomes 50%+ of company revenue by FY27. If not, management gets a one-way ticket to the Aaj Tak debate shows.
Organic Chem Rev187 CrQ3 FY26 (9MFY26: 84%)
Inorganic Chem Rev33 CrQ3 FY26 (+35% YoY)
Neogen Ionics Rev12 CrQ3 FY26 (Scale-up Phase)
FY27 Battery Target₹400-500 Cr33-40x Growth
The Tech Edge: Neogen licensed manufacturing technology from MUIS (a JV between Mitsubishi Chemical Corp and UBE Corporation of Japan) — the oldest and most proven electrolyte producer in the world. This is not DIY experimentation. This is proven tech transfer. But the market is still skeptical because, historically, Neogen made bromine compounds, not battery chemicals. The cognitive dissonance is real.
💬 Will Neogen be a battery materials leader by FY28, or will they spend ₹1,500 crore on three new plants and discover the market is already saturated? Drop your prediction!
04 — Financials Overview
Q3 FY26: The Recovery Masking the Pain
Result type: Quarterly Results (9M FY26 Ended Dec 31, 2025) | Q3 EPS: ₹1.40 | Annualised EPS (Q3×4): ₹5.60 | FY25 Full-year EPS: ₹13.20
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 220.02 | 201.43 | 208.66 | +9.2% | +5.4% |
| Operating Profit | 31.90 | 34.64 | 29.96 | -7.9% | +6.5% |
| OPM % | 14.5% | 17.2% | 14.4% | -270 bps | +10 bps |
| PAT | 3.69 | 10.01 | 3.37 | -63.1% | +9.5% |
| EPS (₹) | 1.40 | 3.79 | 1.28 | -63.1% | +9.4% |
The Narrative Flip: Revenue up 9%. OPM down 270 basis points. PAT down 63%. So why is the stock up 25%? Because management convinced everyone the pain is “temporary transition costs” — Neogen Ionics ramp-up overhead, toll manufacturing due to Dahej bottleneck, higher finance costs. But here’s the kicker: management also said these cost pressures will reverse as Dahej stabilizes and battery production starts in-house. Is this credible? Maybe. Is it also the oldest story in distressed equity turnarounds? Absolutely. P/E: 134x on annualized Q3 EPS. That’s not valuation. That’s a lottery ticket.
05 — Valuation: The YOLO Zone
Fair Value Range: Use At Your Own Risk
Method 1: Historical P/E Based
FY25 full-year EPS was ₹13.20. Historical 3-year average P/E for specialty chemicals: ~25-30x. Normalized earnings (stripping fire impact and one-time costs) could be ~₹10-12 per share range.
Range: ₹250 – ₹360
Method 2: DCF on Normalized Basis
Assume Neogen achieves ₹400-500 crore battery revenue by FY27 + ₹700+ crore organic revenue. Blended margins recover to 12-14%. Conservative WACC: 12%.
FY27 Net Profit: ~₹100-120 Cr (normalized)
FY28 Net Profit: ~₹180-200 Cr (battery scaling)
Terminal Growth: 4%; Capex: ₹800 Cr (under-utilized)
PV Estimate: ~₹650-850 Cr Enterprise Value
Range: ₹245 – ₹320
Method 3: Comparable Company Valuation
Specialty chemicals peers (Pidilite, Deepak Nitrite, Atul) trade at 30-60x P/E on stable earnings. Neogen is in transition (higher risk) with unproven battery scale-up (lower visibility). Haircut: 40-50%.
Normalized EPS ~₹10-12; Justified P/E 15-20x (vs. peer 30-50x):
Range: ₹150 – ₹240
⚠️ EduInvesting Fair Value Range: ₹150 – ₹360. The wide band reflects uncertainty around battery scale-up execution, insurance claim timing, and debt refinancing. CMP ₹1,354 is outside this range — trading on hopes of transformative battery growth, not current fundamentals. This fair value range is for educational purposes only and is not investment advice.
06 — What’s Cooking: Fire, Plants, JV, and Equity Raises
More Plots Than A Succession Season
